Merck Beats Q1 Estimates, Raises 2026 Guidance, Wins FDA Nod for HIV Drug
Merck (MRK) reported Q1 2026 results that beat estimates, slightly raised full-year 2026 sales guidance to $65.8-$67.0 billion, and received FDA approval for its HIV regimen IDVYNSO, highlighting strong contributions from oncology and animal health.
Key Numbers
Merck & Co., Inc. (NYSE: MRK) reported first-quarter 2026 results that surpassed analyst expectations, accompanied by a modest upward revision to its full-year 2026 sales guidance to a range of $65.8-$67.0 billion. The company highlighted strong contributions from its oncology and animal health segments, as well as new product launches. Concurrently, Merck advanced its pipeline with FDA approval of the HIV regimen IDVYNSO, multiple priority reviews related to KEYTRUDA, and new renal cancer data.
Key Financial Results
| Metric | Q1 2026 | vs. Expectations |
|---|---|---|
| Revenue | Not disclosed | Beat |
| Net Income | Not disclosed | — |
| EPS | Not disclosed | Beat |
Highlights from the Report
- Raised full-year 2026 revenue guidance to $65.8-$67.0 billion.
- FDA approval of IDVYNSO for HIV treatment.
- Multiple priority reviews for KEYTRUDA.
- New renal cancer data presented.
Future Guidance
Merck raised its 2026 revenue guidance to $65.8-$67.0 billion, up from previous guidance, reflecting confidence in continued growth.
Impact on Stock
The stock reaction was not specified in the source, but positive results and raised guidance typically support the stock.
What This Means for Investors
The results underscore Merck's strong core business and diversified portfolio, with pipeline advancements. Investors await full financial details to assess performance accurately.
Frequently Asked Questions
Found this useful? Share it